Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review

British Journal of Clinical Pharmacology

Volumn 73, Issue 1, 2012, Pages 16-26

  Nijenhuis, Cynthia M ^a   Ter Horst, Peter G J ^b   De Jong van den Berg, Lolkje T W ^a   Wilffert, Bob ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

Enteric nervous system; Norepinephrine transporter; Ontogeny; Selective serotonin re uptake inhibitor; Serotonin re uptake transporter; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORCLOMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

DEVELOPMENTAL DISORDER; DRUG MECHANISM; ENTERIC NERVOUS SYSTEM DEVELOPMENT DISORDER; ENVIRONMENTAL EXPOSURE; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; INFANTILE HYPERTROPHIC PYLORIC STENOSIS; INTERSTITIAL CELL OF CAJAL; INTESTINE INNERVATION; MAJOR DEPRESSION; NERVOUS SYSTEM DEVELOPMENT; ONTOGENY; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; ENTERIC NERVOUS SYSTEM; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 83155192796     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04075.x     Document Type: Review

References (86)

1. Chatillon O, Even C. [Antepartum depression: prevalence, diagnosis and treatment]. Encephale 2010; 36: 443-51.
2. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65: 600-6.
3. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 863-70.
4. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2: 29-36.
5. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993-6.
6. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42: 95-100.
7. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66: 695-705.
8. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87.
9. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 18-27.
10. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 1075-85.
11. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17: 701-4.
12. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301-8.
13. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569.
14. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29: 918-26.
15. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-83.
16. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83: 68-76.
17. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16: 1086-94.
18. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-92.
19. Derijks HJ, Heerdink ER, Janknegt R, De Koning FH, Olivier B, Loonen AJM, Egberts AC. Visualizing pharmacological activities of antidepressants: a novel approach. Open Pharmacol J 2008; 2: 54-62.
20. Bakker MK, De Walle HE, Wilffert B, de Jong-Van den Berg LT. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010; 19: 808-13.
21. Gershon MD. 5-HT (serotonin) physiology and related drugs. Curr Opin Gastroenterol 2000; 16: 113-20.
22. Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 1999; 89: 243-65.
23. Hu YF, Caron MG, Sieber-Blum M. Norepinephrine transport-mediated gene expression in noradrenergic neurogenesis. BMC Genomics 2009; 10: 151.
24. Li Z, Caron MG, Blakely RD, Margolis KG, Gershon MD. Dependence of serotonergic and other nonadrenergic enteric neurons on norepinephrine transporter expression. J Neurosci 2010; 30: 16730-40.
25. Gershon MD. V. Genes, lineages, and tissue interactions in the development of the enteric nervous system. Am J Physiol 1998; 275: G869-73.
26. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 2009; 158 (Suppl. 1): S1-254.
27. Burns AJ. Migration of neural crest-derived enteric nervous system precursor cells to and within the gastrointestinal tract. Int J Dev Biol 2005; 49: 143-50.
28. Burns AJ, Thapar N. Advances in ontogeny of the enteric nervous system. Neurogastroenterol Motil 2006; 18: 876-87.
29. Furness JB. The Enteric Nervous System. Oxford: Blackwell Publishing, 2005.
30. Wallace AS, Burns AJ. Development of the enteric nervous system, smooth muscle and interstitial cells of Cajal in the human gastrointestinal tract. Cell Tissue Res 2005; 319: 367-82.
31. Schöni-Affolter F, Dubuis-Grieder C, Strauch E. Human Embryology. Carnegie Stages. University of Fribourg, Lausanne, Bern 2011. Available at (last accessed 20 August 2011).
32. Fiorica-Howells E, Maroteaux L, Gershon MD. Serotonin and the 5-HT(2B) receptor in the development of enteric neurons. J Neurosci 2000; 20: 294-305.
33. Gershon MD, Rothman TP, Joh TH, Teitelman GN. Transient and differential expression of aspects of the catecholaminergic phenotype during development of the fetal bowel of rats and mice. J Neurosci 1984; 4: 2269-80.
34. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 15-30.
35. Kong EK, Peng L, Chen Y, Yu AC, Hertz L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 2002; 27: 113-20.
36. Tharayil VS, Wouters MM, Stanich JE, Roeder JL, Lei S, Beyder A, Gomez-Pinilla PJ, Gershon MD, Maroteaux L, Gibbons SJ, Farrugia G. Lack of serotonin 5-HT2B receptor alters proliferation and network volume of interstitial cells of Cajal in vivo. Neurogastroenterol Motil 2010; 22: 462-9; e109-10.
37. Wouters MM, Farrugia G, Schemann M. 5-HT receptors on interstitial cells of Cajal, smooth muscle and enteric nerves. Neurogastroenterol Motil 2007; 19 (Suppl. 2): 5-12.
38. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 3-14.
39. Zhou X, Galligan JJ. Synaptic activation and properties of 5-hydroxytryptamine(3) receptors in myenteric neurons of guinea pig intestine. J Pharmacol Exp Ther 1999; 290: 803-10.
40. Roth KA, Hermiston ML, Gordon JI. Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants. Proc Natl Acad Sci USA 1991; 88: 9407-11.
41. Tutton PJ. The influence of serotonin on crypt cell proliferation in the jejunum of rat. Virchows Arch B Cell Pathol 1974; 16: 79-87.
42. Tutton PJ, Barkla DH. Neural control of colonic cell proliferation. Cancer 1980; 45: 1172-7.
43. Pham TD, Gershon MD, Rothman TP. Time of origin of neurons in the murine enteric nervous system: sequence in relation to phenotype. J Comp Neurol 1991; 314: 789-98.
44. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, Gershon MD. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001; 21: 6348-61.
45. Neal KB, Parry LJ, Bornstein JC. Strain-specific genetics, anatomy and function of enteric neural serotonergic pathways in inbred mice. J Physiol 2009; 587: 567-86.
46. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
47. Fritz JD, Jayanthi LD, Thoreson MA, Blakely RD. Cloning and chromosomal mapping of the murine norepinephrine transporter. J Neurochem 1998; 70: 2241-51.
48. Matthies HJ, Han Q, Shields A, Wright J, Moore JL, Winder DG, Galli A, Blakely RD. Subcellular localization of the antidepressant-sensitive norepinephrine transporter. BMC Neurosci 2009; 10: 65.
49. Hao MM, Moore RE, Roberts RR, Nguyen T, Furness JB, Anderson RB, Young HM. The role of neural activity in the migration and differentiation of enteric neuron precursors. Neurogastroenterol Motil 2010; 22: e127-37.
50. Askew N. An overview of infantile hypertrophic pyloric stenosis. Paediatr Nurs 2010; 22: 27-30.
51. Panteli C. New insights into the pathogenesis of infantile pyloric stenosis. Pediatr Surg Int 2009; 25: 1043-52.
52. Piotrowska AP, Solari V, Puri P. Distribution of heme oxygenase-2 in nerves and interstitial cells of Cajal in the normal pylorus and in infantile hypertrophic pyloric stenosis. Arch Pathol Lab Med 2003; 127: 1182-6.
53. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology. Philadelphia, PA: Churchill Livingstone Elsevier, 2007; 557-74.
54. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59 (Suppl. 4): 5-14.
55. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003; 160: 90-9.
56. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009; 8: 317-29.
57. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 1999; 128: 13-20.
58. Thomas DR, Gager TL, Holland V, Brown AM, Wood MD. m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. Neuroreport 1996; 7: 1457-60.
59. Zhang S, Li B, Lovatt D, Xu J, Song D, Goldman SA, Nedergaard M, Hertz L, Peng L. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'. Neuron Glia Biol 2010; 6: 113-25.
60. Etienne N, Schaerlinger B, Jaffre F, Maroteaux L. [The 5-HT2B receptor: a main cardio-pulmonary target of serotonin]. J Soc Biol 2004; 198: 22-9.
61. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121: 69-88.
62. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-33.
63. Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. Biol Psychiatry 2006; 59: 287-90.
64. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 1996; 126: 234-40.
65. Anji A, Kumari M, Sullivan Hanley NR, Bryan GL, Hensler JG. Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin. Neuropharmacology 2000; 39: 1996-2005.
66. Buckholtz NS, Zhou DF, Freedman DX. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. Life Sci 1988; 42: 2439-45.
67. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment. Eur J Pharmacol 1994; 269: 201-8.
68. Leysen JE, Janssen PF, Niemegeers CJ. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Eur J Pharmacol 1989; 163: 145-9.
69. McKenna DJ, Nazarali AJ, Himeno A, Saavedra JM. Chronic treatment with (+/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain. Neuropsychopharmacology 1989; 2: 81-7.
70. Pranzatelli MR. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Biochem Pharmacol 1991; 42: 1099-105.
71. Pranzatelli MR, Murthy JN, Tailor PT. Novel regulation of 5-HT1C receptors: down-regulation induced both by 5-HT1C/2 receptor agonists and antagonists. Eur J Pharmacol 1993; 244: 1-5.
72. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 1998; 79: 231-57.
73. Uphouse L. Multiple serotonin receptors: too many, not enough, or just the right number? Neurosci Biobehav Rev 1997; 21: 679-98.
74. Enguix MJ, Sanchez L, Villazon M, Brea J, Tristan H, Caruncho HJ, Cadavid MI, Loza MI. Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 79-90.
75. Huizinga JD. Physiology and pathophysiology of the interstitial cell of Cajal: from bench to bedside. II. Gastric motility: lessons from mutant mice on slow waves and innervation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1129-34.
76. Iino S, Horiguchi K. Interstitial cells of Cajal are involved in neurotransmission in the gastrointestinal tract. Acta Histochem Cytochem 2006; 39: 145-53.
77. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-41.
78. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 1997; 36: 621-9.
79. Kallen BA, Otterblad OP. Maternal drug use in early pregnancy and infant cardiovascular defect. ReprodToxicol 2003; 17: 255-61.
80. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk. Baltimore, MD: Williams & Wilkins, 2008.
81. Del Rio J, Montero D, De Ceballos ML. Long-lasting changes after perinatal exposure to antidepressants. ProgBrain Res 1988; 73: 173-87.
82. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J ClinPharmacol 1999; 55: 503-08.
83. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889-95.
84. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, Newton SS, Duman RS. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010; 16: 1328-32.
85. Kubera M, Grygier B, Arteta B, Urbanska K, Basta-Kaim A, Budziszewska B, Leskiewicz M, Kolaczkowska E, Maes M, Szczepanik M, Majewska M, Lason W. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep 2009; 61: 1113-26.
86. Heikkinen T, Ekblad U, Laine K. Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. Psychopharmacology (Berl) 2001; 153: 450-4.